TACSTD2 and neoplasm: Sacituzumab Govitecan (SG; Trodelvy or IMMU-132) is an ADC approved for use in pre-treated BC patients: an anti-TROP2 mAb delivers the cytotoxic SN-38 directly to the TROP2-expressing tumor cells.